Spectrum Pharmaceuticals, Inc. Business Operations Contracts & Agreements

28 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Second Amendment to Supply Agreement, dated as of January 1, 2022, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2023
First Amendment to Supply Agreement, dated as of December 6, 2019, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2023
Supply Agreement, dated as of February 28, 2018, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
NY
2023
Form of Indemnification Agreement of Spectrum Pharmaceuticals, Inc
Indemnification Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
DE
2020
SPECTRUM PHARMACEUTICALS CAYMAN, L.P. and MUNDIPHARMA MEDICAL COMPANY SUPPLY AGREEMENT
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
NY
2016
ALLOS THERAPEUTICS, INC. and MUNDIPHARMA MEDICAL COMPANY AMENDED AND RESTATED SUPPLY AGREEMENT TABLE OF CONTENTS
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
CO
2013
SUPPLY AGREEMENT
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2013
MANUFACTURING AND SUPPLY AGREEMENT
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2012
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO...
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2012
TENDER AND VOTING AGREEMENT
Voting Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2012
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
CA
2011
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2011
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2011
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2011
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2011
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2011
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
NV
2010
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
CA
2010
Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2010
Maximizing the growth potential for our marketed drugs, Fusilev and Zevalin. The companys near-term outlook depends on sales and marketing successes associated with our two...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
NY
2009
Maximizing the growth potential for our marketed drugs, Fusilev and Zevalin. The companys near-term outlook depends on sales and marketing successes associated with our two...
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
DE
2009
MANUFACTURING AND SUPPLY AGREEMENT
Supply Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2006
Eight proprietary drug product candidates, or drug products with respect to which we have patent rights, either directly or through licensing, under development, including one in...
Development Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2006
Eight proprietary drug product candidates, or drug products with respect to which we have patent rights, either directly or through licensing, under development, including one in...
Development Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
DE
2006
Eight proprietary drug product candidates, or drug products with respect to which we have patent rights, either directly or through licensing, under development, including one in...
Development Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2006
Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2001
Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2001
Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co
Sales Agreements
Spectrum Pharmaceuticals, Inc.
Biotechnology
2001